MR imaging contrast agents - What's in a name?

Journal of Magnetic Resonance Imaging

Volumn 7, Issue 1, 1997, Pages 1-4

  Mitchell, Donald G ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

MR imaging (MRI) contrast agents; Nomenclature

Indexed keywords

CONTRAST MEDIUM; ECHOVIST; FERRIC AMMONIUM CITRATE; FERRISELZ; FERRISTENE; FERUMOXSIL; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM CHLORIDE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOLINIUM ZEOLITE; GADOTERIC ACID; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; MANGAFODIPIR; MANGANESE CHLORIDE; PERFLUOROOCTYL BROMIDE; SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

CONTRAST ENHANCEMENT; DRUG CLASSIFICATION; DRUG FORMULATION; NOMENCLATURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, ORAL; CONTRAST MEDIA; HUMANS; MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; TERMINOLOGY;

EID: 0031404149     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmri.1880070102     Document Type: Review

References (29)

1. Wolfe GL, Fobben ES. Tissue proton T1 and T2 response to gadolinium-DTPA injection in rabbits: a potential contrast agent for MR imaging. Invest Radiol 1984; 19:324-328.
2. Weinmann HJ, Brasch RC, Press WR, et al. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. AJR 1984; 142:619-624.
3. Carr DH, Brown J, Bydder GM, et al. Gadolinium-DTPA as a contrast agent in MRI: initial clnical experience in 20 patients. AJR 1984; 143:215-224.
4. Hamm B, Staks T, Muhler A, Bollow M, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195:785-792.
5. Muhler A, Weinmann H. Biodistribution and excretion of 153 Gd-labeled gadolinium ethoxybenzyl diethylenetriamine penta-acetic acid following repeated intravenous administration to rats. Acad Radiol 1995; 2:313-318.
6. Giovagnoni A, Paci E. Liver III: gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). MRI Clin North Am 1996; 4:61-72.
7. Cavagna FM, Maggioni F, Vincinanca E, et al. Gd-BOPTA/Dimeg: experimental disease imaging. Magn Reson Med 1991; 22: 329-333.
8. Vogl TJ, Pegios W, McMahon C, et al. Gadobenate dimeglumine: a new contrast agent for MR imaging: preliminary evaluation in healthy volunteers. Am J Roentgenol 1992; 157:887-892.
9. Wolf GL, Baum L. Cardiovascular toxicity and tissue proton T1 response to manganese injection in the dog and rabbit. AJR 1983; 141:193-197.
10. Davidsson L, Lonnerdal B, Sandstrom B, Kunz C, Keen CL. Identification of transferrin as the major plasma carrier protein for manganese introduced orally or intravenously or after in vitro addition in the rat. J Nutr 1989; 119:1461-1464.
11. Marchal G, Ni Y, Zhang X, Yu J, Lodemann KP, Baert AL. Mn-DPDP enhanced MRI in experimental bile duct obstruction. J Comput Assist Tomogr 1993; 17:290-296.
12. Mitchell DG, Outwater EK, Matteucci T, Rubin DL, Chezmar JL, Saini S. Adrenal gland enhancement at MR imaging with Mn-DPDP. Radiology 1995; 194:783-787.
13. Gehl H, Urhahn R, Bohndorf K. Mn-DPDP in MR imaging of pancreatic adenocarcinoma: initial clinical experience. Radiology 1993; 186:795-798.
14. Bernardino ME, Young SW, Lee JKT, Weinreb JC. Hepatic MR imaging with Mn-DPDP: safety, image quality, and sensitivity. Radiology 1992; 183:53-58.
15. Petersein J, Saini S, Weissleder R. Liver II: iron oxide-based reticuloendothelial contrast agents for MR imaging: clinical review. MRI Clin N Am 1996; 4:53-60.
16. Hagspiel K, Neidl K, Eichenberger A, Weder W, Marincek B. Detection of liver metastases: comparison of superparamagnetic iron oxide - enhanced and unenhanced MR imaging at 1.5T with dynamic CT, intraoperative US, and percutaneous US. Radiology 1995; 196:471-478.
17. Grandin C, Van Beers BE, Robert A, et al. Benign hepatocellular tumors: MRI after superparamagnetic iron oxide administration. J Comput Assist Tomogr 1995; 19:412-418.
18. Hahn PF, Stark DD, Weissleder R, et al. Clinical application of superparamagnetic iron oxide to MR imaging of tissue perfusion in vascular liver tumors. Radiology 1990; 174:361-366.
19. Hamm B, Staks T, Taupitz M, Maibauer R, et al. Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide. JMRI 1994; 4: 659-668.
20. McLachlan SJ, Morris MR, Lucas MA, et al. Phase I clinical evaluation of a new iron oxide MR contrast agent. JMRI 1994; 4:301-307.
21. Saini S, Edelman RR, Sharma P, et al. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227). AJR 1995; 164:1147-1152.
22. Anzai Y, Blackwell KE, Hirshocwitz SL, Rogers JW, et al. Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer. Radiology 1994; 192:709-715.
23. Hahn PF, Stark DD, Lewis JM, et al. First clinical trial of a new superparamagnetic iron oxide for use as an oral gastrointestinal contrast agent in MR imaging. Radiology 1990; 175: 695-700.
24. Bernardino ME, Weinreb JC, Mitchell DG, Small WC, Morris M. Safety and optimum concentration of a manganese chloride-based oral MR contrast agent. JMRI 1994; 4:872-876.
25. Vlahos L, Gouliamos A, Athanasopoulou A, Kotoulas G, et al. A comparative study between Gd-DTPA and oral magnetic particles (OMP) as gastrointestinal (GI) contrast agents for MRI of the abdomen. Magn Reson Imaging 1994; 12:719-726.
26. Heusler-Haldemann RC, Wight E, Marincek B. Oral superparamagnetic contrast agent (ferumoxsil): tolerance and efficacy in MR imaging of gynecologic diseases. JMRI 1995; 4:385-381.
27. Mitchell DG, Vinitski S, Haidet K, et al. Comparison of Kaopectate with barium for negative and positive enteric contrast at MR imaging. Radiology 1991; 181:475-480.
28. Hiraishi K, Narabayashi I, Fujita O, Yamamoto K, Sagami A. Blueberry juice: preliminary evaluation as an oral contrast agent in gastrointestinal MR imaging. Radiology 1995; 194:119-123.
29. Marti-Bonmati L, Vilar J, Panagua JC, et al. High density barium sulphate as an MRI oral contrast. Magn Reson Imaging 1991; 9:259-261.